Patents Examined by Padmashri Ponnaluri
  • Patent number: 7173005
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: February 6, 2007
    Assignees: Antyra Inc., Novo Nordisk A/S
    Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
  • Patent number: 7128903
    Abstract: A pharmaceutical preparation useful for treating a skin or mucous membrane lesion is provided. The pharmaceutical preparation including, as active ingredients, a therapeutically effective amount of trichloroacetic acid and hydrochloric acid, or trichloroacetic acid and formic acid or all three of these acids and optionally a crosslinking/fixating/preserving agent. Additional preparations are also described.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: October 31, 2006
    Assignee: Innovative Pharmaceutical Concepts (IPC) Inc.
    Inventor: Pinchas Burstein
  • Patent number: 7122321
    Abstract: The present invention provides a method for functionally classifying a protein that is capable of unfolding due to a thermal change. The method comprises screening one or more of a multiplicity of different molecules for their ability to shift the thermal unfolding curve of the protein, wherein a shift in the thermal unfolding curve indicates that the molecule binds to the protein or affects the stability in a measurable way; generating an activity spectrum for the protein wherein the activity spectrum reflects a set of molecules, from the multiplicity of molecules, that shift the thermal unfolding curve, of the protein and therefore are ligands that bind to the protein, comparing the activity spectrum for the protein to one or more functional reference spectrum lists; and classifying the protein according to the set of molecules in the multiplicity of different molecules that shift the thermal unfolding curve of the protein.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: October 17, 2006
    Assignee: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Inventors: Michael W Pantoliano, Francis R Salemme, Theodore E Carver, Jr.
  • Patent number: 7115566
    Abstract: The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine?pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: October 3, 2006
    Assignee: University of Florida
    Inventors: Nicholas Stephen Bodor, Maria Grant
  • Patent number: 7112661
    Abstract: The present invention is directed to a method of selecting a clone that binds to human platelet glycoprotein Ib alpha using a human variable heavy chain and variable light chain immunoglobulin library. The invention is further directed to isolated nucleic acid molecules encoding a variable heavy chain or variable light chain region of an antibody, wherein the antibody binds to human platelet glycoprotein Ib alpha and inhibits aggregation of platelets. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for producing the variable heavy chain or the variable light chain region. An isolated variable heavy chain or variable light chain region of an antibody, wherein the antibody binds to human platelet glycoprotein Ib alpha and inhibits aggregation of platelets, is also provided. An antibody comprising the variable heavy chain or variable light chain regions is provided, as is a composition comprising the antibody and a carrier.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: September 26, 2006
    Assignee: The Research Foundation of State University of New York
    Inventor: Jonathan L. Miller
  • Patent number: 7105290
    Abstract: The present invention relates to a method for determining whether a compound is capable of binding to a BMP receptor kinase protein complex, the method comprising introducing a sample comprising the compound to the BMP receptor kinase protein complex and allowing the compound to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and the BMP receptor kinase protein BRK-3. The invention further relates to a method for determining the concentration of a BMP receptor ligand in a clinical sample, the met-hod comprising introducing the sample comprising the ligand to a BMP receptor kinase protein complex and allowing the ligand to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and BMP receptor kinase protein BRK-3.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: September 12, 2006
    Assignee: The Procter & Gamble Company
    Inventor: Jan Susan Rosenbaum
  • Patent number: 7097839
    Abstract: Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 29, 2006
    Assignee: Thomas Jefferson University
    Inventor: Scott A. Waldman
  • Patent number: 7097974
    Abstract: A method for producing a support for determining analytes. The method comprises the steps of (a) providing a support comprising at least one channel, comprising a conduit having an intake and an outlet for passing fluid from the intake to the outlet, in the support body, (b) passing liquid with building blocks for synthesizing polymeric receptors through the channel or channels of the support body, (c) site- and/or time-specifically immobilizing the receptor building blocks in each case on predetermined positions in the channel or channels by illumination and (d) repeating steps (b) and (c) until the required receptors have been synthesized in each case on the predetermined positions.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: August 29, 2006
    Assignee: febit biotech GmbH
    Inventors: Cord F. Stähler, Peer F. Stähler, Manfred Müller, Fritz Stähler, Hans Lindner
  • Patent number: 7094609
    Abstract: A method for preparing very large spatially-addressable arrays of chemical compounds by light-directed synthesis is provided, wherein the light is provided by a laser and the compounds are arrayed on a rotating disc in a CD-ROM format. A method for assaying the resulting array with a CD-ROM mechanism is also provided.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: August 22, 2006
    Assignees: Burstein Technologies, Inc., Nagaoka & Co. Ltd.
    Inventor: James Paul Demers
  • Patent number: 7090976
    Abstract: The invention relates to methods and compositions utilizing Renilla green fluorescent proteins (rGFP), and Ptilosarcus green fluorescent proteins (pGFP). In particular, the invention relates to the use of Renilla GFP or Ptilosarcus GFP proteins as reporters for cell assays, particularly intracellular assays, including methods of screening libraries using rGFP or pGFP.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: August 15, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: David Anderson, Beau Peelle
  • Patent number: 7083917
    Abstract: The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: August 1, 2006
    Assignees: Cornell Research Foundation, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Regents of the University of Minnesota
    Inventors: Francis Barany, George Barany, Robert P. Hammer, Maria Kempe, Herman Blok, Monib Zirvi
  • Patent number: 7078164
    Abstract: A method is disclosed for screening potential catalysts for polymerization performance. The method includes the steps of reacting a potential catalyst with at least a first monomer under polymerization conditions, determining the polymerization performance of the catalyst with the at least first monomer, and using the determination as a predictor for the polymerization performance of the catalyst for at least a second monomer, wherein the first and second monomers are different from each other and the first monomer is an olefin other than ethylene. The method provides a useful, concrete and tangible result that has particular value for identifying appropriate catalysts for olefin polymerization and copolymerization.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: July 18, 2006
    Assignee: Symyx Technologies, Inc.
    Inventors: Gary M. Diamond, Christopher Goh, Margarete K. Leclerc, Vince Murphy, Howard W. Turner
  • Patent number: 7078166
    Abstract: The invention describes the display of exogenous polypeptides on filamentous phage using a fusion between the exogenous polypeptide and phage pVII or pIX proteins. In particular, phage particles and phagemid vectors are described for expression and display of heterodimeric proteins such as antibody Fv heterodimers in combinatorial libraries, and uses thereof.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: July 18, 2006
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Peter Wirsching, Richard A. Lerner, Changshou Gao
  • Patent number: RE39545
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: April 3, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE39571
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: April 17, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE39606
    Abstract: The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or sequence of the oligomer. In a preferred embodiment of the present invention the identifier tag is a microchip that is pre-encoded or encodable with information that is related back to a detector when the identifier tag is pulsed with electromagnetic radiation.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: May 1, 2007
    Assignee: Nexus Biosystems, Inc.
    Inventor: John Cargill
  • Patent number: RE47103
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 30, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Patent number: RE47131
    Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: November 20, 2018
    Assignee: Therapeutic Human Polyclonals, Inc.
    Inventors: Josef Platzer, Roland Buelow, Wim van Schooten
  • Patent number: RE47245
    Abstract: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 19, 2019
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: RE47320
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier